IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)

The study is intended to assess the safety and efficacy of neoadjuvant combination of IPH5201 and durvalumab in addition to standard chemotherapy and adjuvant combination of IPH5201 and durvalumab in untreated patients with resectable, early-stage (stage II to IIIA) non-small cell lung cancer (NSCLC).

Trial Details

NCT ID
NCT05742607
Phase
PHASE2
Sponsor
Innate Pharma
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • IPH5201 + durvalumab + standard chemotherapy
Locations (sample)
  • St. Petersburg, Florida, United States|27.77086,-82.67927
  • Tampa, Florida, United States|27.94752,-82.45843
  • Chicago, Illinois, United States|41.85003,-87.65005
  • Lake Success, New York, United States|40.77066,-73.71763
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Newly diagnosed and previously untreated patients with histologically or cytologically documented NSCLC resectable (Stage IIA to Stage IIIA) diseas…
  • WHO Performance Status or Eastern Cooperative Oncology Group of 0 or 1.
  • Adequate organ and marrow function.
  • Must have a life expectancy of at least 12 weeks.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →